AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has completed a Phase 3 clinical study titled ‘RESOLUTE,’ aimed at evaluating the efficacy and safety of Benralizumab in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) who have a history of frequent exacerbations and elevated peripheral blood eosinophils. The study’s primary objective was to assess the treatment’s impact on reducing COPD exacerbations, a significant concern for patients with this condition.
The intervention tested in this study was Benralizumab, a biological treatment administered subcutaneously. It was given every four weeks for the first three doses and then every eight weeks. The purpose of Benralizumab is to reduce exacerbations in COPD patients by targeting and reducing eosinophils, which are known to contribute to inflammation in COPD.
The study was designed as a multicenter, randomized, double-blind, placebo-controlled trial with a parallel-group intervention model. It involved triple masking, meaning that the participant, care provider, and investigator were unaware of the treatment allocations. The primary purpose of the study was treatment-focused, aiming to provide a new therapeutic option for COPD patients.
The study began on August 26, 2019, and reached its primary completion at Week 56, with the last update submitted on August 18, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for when results might influence market dynamics.
The completion of this study could have significant implications for AstraZeneca’s stock performance and investor sentiment, as successful results may position Benralizumab as a leading treatment for COPD, potentially increasing market share. Competitors in the respiratory treatment market will be closely monitoring these developments, as any breakthrough could shift market dynamics.
The study is now completed, and further details are available on the ClinicalTrials portal.